| 标题 |
 专利、报告等 Efficacy, Cost Analysis, and UTI Prevalence of Dapagliflozin and Its Combinations in Type 2 Diabetes Mellitus: A Prospective Observational Study 达格列净及其联合用药治疗2型糖尿病的疗效、成本分析和UTI患病率：一项前瞻性观察研究
相关领域
达帕格列嗪
二甲双胍
观察研究
医学
泌尿系统
2型糖尿病
内科学
糖尿病
泌尿科
内分泌学
|
| 备注 |
尚未在任何主流数据库（PubMed、PMC、Scopus、Web of Science、DOAJ、CNKI 等）中以“全文”形式公开发布。目前的记录仅停留在会议摘要或投稿阶段。
💡 该求助存在备注，如果存在信息冲突，请以备注为准
|
| 网址 | |
| DOI | |
| 其它 |
作者：Ramesh Petchi, R., G. S. Devika, P. Nandini, B. Reshma and V. S. Prasanth 年份：2024 摘要：Background: Type 2 diabetes mellitus(T2DM) is a chronic metabolic disorder carrying an enormous burden of morbidity and mortality because of its characteristic complications, many of which are preventable with strict glycemic control. Initial management of T2DM consists of non-pharmacological interventions; if those fail, an oral anti-diabetic drug, most typically metformin is started. Combination therapy is initiated only when monotherapy fails to achieve glycemic control. Currently, Dapagliflozin may be considered a second line agent to treat patients with T2DM and has the potential to provide a first line option particularly for patients with contraindications or lack of glycemic control on metformin, the conventional first line agent. |
| 求助人 | |
| 下载 | |
|
温馨提示：该文献已被科研通 学术中心 收录，前往查看
科研通『学术中心』是文献索引库，收集文献的基本信息（如标题、摘要、期刊、作者、被引量等），不提供下载功能。如需下载文献全文，请通过文献求助获取。
|
PDF的下载单位、IP信息已删除
(2025-6-4)
Nole
GingerF
cdercder
罗Eason
null
Criminology34
v0id
无极微光
唠叨的大门
anugraphics
DW
今夕何夕
秋风
果果123
OK
Ali
潇洒的惋清
CRUSADER
swhin
LUX
皖公网安备34019202002308
